Alvotech

Equities

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
12.15 ^USD	+2.02%		+0.25%	+5.84%

Jul. 11	Alvotech Closes $965 Million Loan Facility	MT
Jul. 11	Alvotech Closes $965 Million Loan Facility	MT

Alvotech Initiates Study Of Biosimilar Of J&J's Rheumatoid Arthritis Drug SIMPONI

January 17, 2023 at 07:12 am EST

Alvotech announced yesterday the initiation of a pharmacokinetic study for AVT05, a biosimilar referencing Johnson & Johnson's ("J&J") SIMPONI and SIMPONI ARIA (golimumab). SIMPONI is used to treat certain types of rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and ulcerative colitis (UC). The study will assess the pharmacokinetics, safety, and tolerability of AVT05 compared to SIMPONI in healthy adult subjects.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Yoko J. Bian
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York
NY 10018
UNITED STATES
Tel: 212813 8800
E-mail: rmertz@goodwinlaw.com
URL: www.goodwinlaw.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	JOHNSON & JOHNSON	149.9 USD	+0.13%	+2.33%	361B
	ALVOTECH	12.15 USD	+2.02%	+0.25%	3.66B

Latest news about Alvotech

Alvotech Closes $965 Million Loan Facility	Jul. 11	MT
Alvotech Closes $965 Million Loan Facility	Jul. 11	MT
Alvotech Announces Closing of Private Debt Financing	Jul. 11	CI
Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints	Jul. 02	MT
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®	Jul. 02	CI
Alvotech Provides Preliminary Earnings Guidance for the Second Quarter and Six Months Ended June 30, 2024	Jul. 01	CI
Alvotech Reports Preliminary Q2 Revenue; Shares Rise Pre-Bell	Jul. 01	MT
Nordic Stocks Decrease Wednesday; Alvotech Falls Furthest	Jun. 26	DJ
Alvotech Expects to Issue Up to 22 Million Shares Following Bond Conversion	Jun. 26	MT
Alvotech, Advanz Pharma Collaborate to Supply, Commercialize Proposed Biosimilar to Eylea in Europe	Jun. 18	MT
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma	Jun. 18	MT
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea®? Ld/Hd in Europe	Jun. 18	CI
Alvotech Appoints Hjörleifur Pálsson as Director	Jun. 11	CI
Alvotech and STADA Arzneimittel AG Add to Strategic Alliance Through Denosumab Partnership	Jun. 11	CI
Alvotech Signs Biosimilar Marketing Deal With Stada	Jun. 11	MT
Alvotech Expands Alliance with STADA to Include Denosumab Biosimilar	Jun. 11	MT
Alvotech Enters into A New Term Loan Credit Agreement	Jun. 07	CI
Alvotech Secures Loan Facility of up to $965 Million for Upcoming Launches	Jun. 07	MT
Alvotech Secures $965 Million Term Loan Facility	Jun. 07	MT
Alvotech Announces Strategic Refinancing Agreement	Jun. 07	CI
Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	May. 24	MT
Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024	May. 22
Alvotech Raises Revenue Guidance for the Full Year 2024	May. 22	CI
Alvotech Narrows Q1 Loss as Revenue Increases; Shares Head Higher Premarket	May. 22	MT
Alvotech Narrows Q1 Loss as Revenue Increases	May. 22	MT

Chart Alvotech

Duration

Period

More charts

Company Profile

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Companyâs pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alvotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.15 USD

Average target price

17.5 USD

Spread / Average Target

+44.03%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALVOTECH	+5.84%	3.66B
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research